Breaking News
December 10, 2018 - People covered by Michigan’s expanded Medicaid program report improvements in health, finds study
December 10, 2018 - Hazelnuts improve micronutrient levels in older adults
December 9, 2018 - History of Partner Violence Tied to Menopause Symptoms
December 9, 2018 - Clean Up Safely After a Disaster|Natural Disasters and Severe Weather
December 9, 2018 - Drug wholesalers drove fentanyl’s deadly rise, report concludes
December 9, 2018 - Deprescribing could help manage polypharmacy in older adults
December 9, 2018 - Retraction of article “Joy of cooking too much” from journal
December 9, 2018 - FDA Warns of Rare Stroke Risk With MS Drug Lemtrada (Alemtuzumab)
December 9, 2018 - Feds say heroin, fentanyl remain biggest drug threat to US
December 9, 2018 - Eliminating microglia can reverse some aspects of stress sensitization, study shows
December 9, 2018 - New genetic insight could help treat rare debilitating heart and lung condition
December 9, 2018 - MiRagen Therapeutics Announces Final Safety, Biodistribution and Clinical Efficacy Data From Phase 1 Cobomarsen Clinical Trial in Patients With Mycosis Fungoides
December 9, 2018 - Work with your doctor to weigh pros, cons of treatment options for hyperthyroidism
December 9, 2018 - CWRU researcher secures $14.6 million funding for genetic study into Alzheimer’s disease
December 9, 2018 - High intensity statin treatment and adherence could save more lives
December 9, 2018 - Surgery patients use only 1/4 of prescribed opioids, and prescription size matters
December 9, 2018 - AXT offers Phi Optics upgrade to QPI systems for inverted light microscopes
December 9, 2018 - New booklet could help improve conditions of young pupils with albinism
December 9, 2018 - Few Physicians Work in Practices That Use Telemedicine
December 9, 2018 - Older Adults and Oral Health
December 9, 2018 - Health utility values improve after septorhinoplasty
December 9, 2018 - New EU-funded project provides insight into how the brain develops
December 9, 2018 - Expanded use of tele-emergency services can help strengthen rural hospitals
December 9, 2018 - Infections in the Young May Be Tied to Risk for Mental Illness: Study
December 9, 2018 - Profile: Native Hawaiians and Pacific Islanders
December 9, 2018 - Snoring poses greater cardiac risk to women
December 9, 2018 - Researcher takes further steps in understanding how and why cute aggression occurs
December 9, 2018 - Researchers create new light-activated tools for controlling neurons
December 9, 2018 - Spinal cord injury disrupts the body’s internal clock, study shows
December 9, 2018 - Babies recognize nested structures similar to our grammar
December 9, 2018 - UT Austin researcher receives $2.5 million CZI grant for neurodegenerative disease research
December 9, 2018 - Sleep problems found to be prevalent and increasing among college students
December 9, 2018 - Study reveals why some children are susceptible to the effects of maltreatment
December 9, 2018 - Study investigates influence of different opioids on driving performance
December 9, 2018 - Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating JZP-258 for the Treatment of Idiopathic Hypersomnia
December 9, 2018 - Eliminating microglia prevents heightened immune sensitivity after stress
December 9, 2018 - Boys with social difficulties are at greatest risk of early substance use
December 9, 2018 - ‘Wrong’ connective tissue cells linked to worse prognosis in breast cancer patients
December 8, 2018 - Chronic, refractory schizophrenia patients benefit from targeted cognitive training
December 8, 2018 - Advertising in kids’ apps more prevalent than parents may realize
December 8, 2018 - New way to trace the transmission histories of rare genetic diseases
December 8, 2018 - ASH: A+CHP Bests CHOP for Peripheral T-Cell Lymphoma
December 8, 2018 - Results of pediatric genomic epilepsy tests often reclassified
December 8, 2018 - New way of controlling HIV latency to completely eradicate the virus
December 8, 2018 - Phasefocus to showcase the Livecyte 2 at ASCB
December 8, 2018 - KHN’s ‘What the Health?’ Is health spending the next big political issue?
December 8, 2018 - Mussels take in microplastic pollution fibers and flush most of them out again
December 8, 2018 - AHA: How to Stop Smoking … for Good
December 8, 2018 - Scientists overturn odds to make Parkinson’s discovery
December 8, 2018 - Health benefits of producing marula vinegar
December 8, 2018 - Failure of critical cellular energy sensor responsible for CKD progression, study finds
December 8, 2018 - Ethnicity can be reliable indicator of gut microbiota diversity
December 8, 2018 - Safe Sleep for Baby | NIH News in Health
December 8, 2018 - Study looks at ways technology can support nutritional needs of Parkinson’s patients
December 8, 2018 - Infant milk allergy is being overdiagnosed say experts
December 8, 2018 - Graphene may one day be used to test for ALS
December 8, 2018 - Houston Methodist launches real-time website to track flu cases
December 8, 2018 - RedHill Announces Positive Top-Line Results from Confirmatory Phase 3 Study with Talicia for H. pylori Infection
December 8, 2018 - A way to measure obesity and health beyond BMI
December 8, 2018 - New diagnostic tools may help identify breast cancer patients who could benefit from targeted therapies
December 8, 2018 - Duke-NUS researchers highlight possible role of bioaerosol sampling in pandemic surveillance
December 8, 2018 - Study quantifies links between alcohol, drug use and violent deaths
December 8, 2018 - Mothers’ stress levels at conception linked to child’s response to life challenges at age 11
December 8, 2018 - MIT researchers develop antimicrobial peptides from South American wasp’s venom
December 8, 2018 - Obesity prevention among low-income, diverse preschool-aged children and parents
December 8, 2018 - Mount Sinai researcher awarded $2.5 million to advance understanding of neurodegenerative diseases
December 8, 2018 - CZI announces funding for open-source software efforts to improve image analysis in biomedicine
December 8, 2018 - New book encompasses the vast history of reproduction
December 8, 2018 - Low-income women in Texas are not receiving contraception after childbirth, study shows
December 8, 2018 - Study expands knowledge about sexuality and gender gaps in political attitudes
December 8, 2018 - Drug reduces hot flash frequency, improves quality of life in breast cancer survivors
December 8, 2018 - Imaging, Biopsy Often Still Needed After Mastectomy
December 8, 2018 - Physical Activity Guidelines for Americans: 2nd edition
December 8, 2018 - Machine learning can improve chemical toxicity prediction
December 8, 2018 - Researchers explore why and how Mediterranean diet may mitigate cardiovascular risk
December 8, 2018 - Multigene test is a helpful decision making tool in breast cancer treatment, study shows
December 8, 2018 - New EZ-2 centrifugal evaporator to safely remove solvents from cytotoxic drug preparations
December 8, 2018 - UMGCCC uses Gammapod radiotherapy to treat breast cancer patients
December 8, 2018 - Men with inflammatory bowel disease have higher prostate cancer risk
December 8, 2018 - Newly developed molecules may provide more reliable relief for people with autoimmune diseases
Cancer patients may experience delayed skin effects of anti-PD-1 therapy

Cancer patients may experience delayed skin effects of anti-PD-1 therapy

image_pdfDownload PDFimage_print
skin
Human skin structure. Credit: Wikipedia

Cancer patients receiving anti-PD-1 therapies who develop lesions, eczema, psoriasis, or other forms of auto-immune diseases affecting the skin may experience those adverse reactions on a delay—sometimes even after treatment has concluded. In a study that provides guidance for physicians and has implications for patient counseling—dermatologists in the Perelman School of Medicine at the University of Pennsylvania found patients developed skin disease a median of four months after starting treatment, though in one case, the effects were not observed until more than three years later. They published their findings in JAMA Dermatology today.

PD-1 is a checkpoint protein on T cells, which are crucial to the immune system’s ability to fight off disease. Anti-PD-1 immunotherapies like pembrolizumab (Keytruda) or nivolumab (Opdivo) turn off the checkpoint, leaving T cells free to do their job. The approach has become standard of care in multiple cancers, including lung cancer and melanoma. About 40 percent of patients treated with these therapies will develop auto-immune diseases affecting the skin, which can include eczema, psoriasis, and lupus-like reactions, among others.

“The impact of these treatments on the skin is well documented, but there has been relatively little focus on the timing of these adverse events—a crucial point that can both inform doctors on what to watch for and aid them as they counsel patients on what to expect,” said the study’s senior author Emily Y. Chu, MD, Ph.D., an assistant professor of Dermatology. Leo L. Wang, BA, MS, a medical student, is the study’s lead author.

Researchers compiled data on 17 patients seen at Penn between 2014 and 2018—all of whom had biopsies of their skin reactions. Twelve had melanoma, while three had squamous cell carcinoma and two had renal cell carcinoma. All patients had metastatic disease.

The study showed 12 of the 17 patients experienced skin disease three months or later after beginning treatment with pembrolizumab or nivolumab. The soonest a reaction developed was two weeks, while the longest was 38 months. In five patients, the reactions attributed to the anti-PD-1 therapy developed after the patients were no longer receiving the drug.

“While we can’t definitively say that the skin reactions occurring after treatment was discontinued are linked to the therapies, the reactions we observed are typical of those frequently attributed to anti-PD-1 drugs,” Chu said. “We also know that tumor responses are durable even after treatment stops, which is further evidence that skin reactions may also develop during this time.”

Chu noted that all of the patients in this study were referred to dermatology by their oncologists. With more oncologists dealing with these common reactions, these symptoms are often addressed during the normal course of treatment, meaning dermatology tends to only see the more severe cases, Chu said.

“Dermatologists need to be aware that these immunotherapies can cause skin reactions with a delayed onset,” Chu said. “Patients are living longer, and we need to be prepared to address the long-term effects of the treatments that make that possible.”


Explore further:
Melanoma therapy tied to cutaneous adverse events

Journal reference:
JAMA Dermatology

Provided by:
Perelman School of Medicine at the University of Pennsylvania

Tagged with:

About author

Related Articles